Capivasertib (Truqap) is a relatively newer treatment, approved in 2023, so it's still making its way into more people's treatment plans. It's used in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
It's typically recommended for people whose cancer cells have certain mutations and who have Show Full Answer
Capivasertib (Truqap) is a relatively newer treatment, approved in 2023, so it's still making its way into more people's treatment plans. It's used in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
It's typically recommended for people whose cancer cells have certain mutations and who have already tried other treatments. MyBCTeam is a great place to connect with others who may be taking capivasertib. Many members share their personal experiences with treatments, including newer ones like this, so you can get real-world insights from people in similar situations.
As always, if you have specific questions about whether capivasertib is right for you, your oncologist is the best person to guide that conversation. 💙
June 22
Join
Your Privacy Choices
